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Introduction
Fibromyalgia (FM) is a chronic pain condition that
is estimated to affect 2–3% of the general population
(1–3). FM is nine times more prevalent in women
than in men (4). FM is characterised by chronic
widespread pain. Common problems related to FM
include fatigue, sleep disturbance, morning stiffness,
paraesthesias, headache and concurrent medical and
psychiatric disorders (5,6). The cause of FM pain is
not known, although it is generally agreed that
patients with FM (5) have a dysregulation of central
sensory processing frequently referred to as ‘central
centralisation’ (6–8). The presence and severity of
FM cannot be determined by objective clinical ﬁnd-
ings, radiographic abnormalities or routinely used
laboratory tests (9). Presently, there is no known
cure for FM. Treatment of FM is focussed on allevi-
ating pain and increasing function.
In 1990, the ACR published criteria to classify FM
for research (5); these criteria require the presence of
chronic widespread pain in combination with tender-
ness on examination at 11 or more of 18 anatomical
sites known as tender points. Publication of the ACR
criteria heralded a dramatic increase in FM research
(6), including studies quantifying the health status
impact of the condition. This review synthesises
information on the health status burden of FM. We
focussed on studies that measured health status with
the 36-item Medical Outcomes Study (MOS) Short-
Form Health Survey (SF-36) (10) or the abbreviated
12-item Short-Form Health Survey (SF-12) (11). The
SF-36 and the SF-12 measure the same concepts of
physical, mental and social functioning. The SF-36
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SUMMARY
Objective: The current review describes how the health status proﬁle of people
with ﬁbromyalgia (FM) compares to that of people in the general population and
patients with other health conditions. Methods: A review of 37 studies of FM
that measured health status with the 36-item Medical Outcomes Study Short-Form
Health Survey (SF-36) or the 12-item Short-Form Health Survey (SF-12). Results:
Studies performed worldwide showed that FM groups were signiﬁcantly more
impaired than people in the general population on all eight health status domains
assessed. These domains include physical functioning, role functioning difﬁculties
caused by physical problems, bodily pain, general health, vitality (energy vs. fati-
gue), social functioning, role functioning difﬁculties caused by emotional problems
and mental health. FM groups had mental health summary scores that fell 1 stan-
dard deviation (SD) below the general population mean, and physical health sum-
mary scores that fell 2 SD below the general population mean. FM groups also
had a poorer overall health status compared to those with other speciﬁc pain con-
ditions. FM groups had similar or signiﬁcantly lower (poorer) physical and mental
health status scores compared to those with rheumatoid arthritis, osteoarthritis,
osteoporosis, systemic lupus erythematosus, myofacial pain syndrome, primary
Sjo ¨gren’s syndrome and others. FM groups scored signiﬁcantly lower than the pain
condition groups mentioned above on domains of bodily pain and vitality. Health
status impairments in pain and vitality are consistent with core features of FM.
Conclusions: People with FM had an overall health status burden that was
greater in magnitude compared to people with other speciﬁc pain conditions that
are widely accepted as impairing.
Review Criteria
Studies in this review were identiﬁed through a
search of electronic databases (MEDLINE: 1990–
2006; EMBASE: 1990–2006). Search terms
included: ‘ﬁbromyalgia’, ‘health status’, ‘quality of
life’, ‘SF-36’ and ‘SF-12’. Reference lists from
published articles were also searched. Studies were
selected if they were published in the English
language between 1990 and (March) 2006 and
assessed health status with a validated version of
the SF-36 or the SF-12.
Message for the Clinic
Although FM is a controversial construct, studies
performed worldwide showed that the health status
proﬁle of people with FM was remarkably
consistent. People with FM had signiﬁcant
impairments in both mental and physical health
status domains. People with FM had a poorer
overall health status than people with speciﬁc pain
conditions that are widely accepted as impairing.
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as opposed to instruments that target a particular
disease. Both instruments permit comparisons across
groups with different health conditions and they
have been widely applied in studies worldwide.
It is important to understand the health status
burden of people with FM. Health status data quan-
tify impairments in physical, mental and social func-
tioning. Such information can highlight areas where
people with FM experience particular difﬁculty and
where healthcare providers may be able to effect
change in clinical status. Data on the relative health
status impact of different health conditions can also
be used to help inform healthcare policy. In particu-
lar, this review focuses on how the health status pro-
ﬁle of people with FM compares to that of people
with painful conditions, such as rheumatoid arthritis
(RA), osteoarthritis (OA), systemic lupus erythemat-
osus (SLE), headache and others. FM is a controver-
sial construct. If studies from around the world were
to reveal a consistent and serious pattern of impair-
ment among people with FM, ﬁndings would stress
the importance of addressing the health status bur-
den of FM, irrespective of debate about how FM
should be classiﬁed.
This review addresses four questions about the
health status burden among people with FM. Which
health status domains appear to be most affected in
people with FM? How does the health status burden
in people with FM compare to that of people in the
general population and patients with other speciﬁc
health conditions? Do health status proﬁles differ
between male and female patients with FM? To what
extent does FM contribute to the overall health sta-
tus burden among people who have another speciﬁc
pain condition at the same time (i.e. a concurrent
condition)?
Methods
Literature search
Studies in the current review were identiﬁed through
searches of electronic databases (MEDLINE from
1990 to 2006; EMBASE from 1990 to 2006). Search
terms included ‘ﬁbromyalgia’, ‘SF-36’, ‘SF-12’, ‘health
status’ and ‘quality of life’. The search strategy
included the term ‘quality of life’ because the SF-36
and the SF-12 are concurrently classiﬁed as measures
of health status and health-related quality of life. Ref-
erence lists of published articles were also manually
searched.
Selection criteria
We selected studies that examined the health status
burden of people with FM using a validated version
of the SF-36 or the SF-12. Studies were included if
they were published in peer-reviewed journals in
the English language between 1990 and (March)
2006.
Classiﬁcation of diagnostic groups
We did not limit the review to studies that used
published classiﬁcation criteria for FM or any other
pain condition, as classiﬁcation criteria developed for
research purposes may not be applied in routine
clinical practice. Of the 37 studies that met criteria
for inclusion in this review, 32 (86%) classiﬁed FM
according to 1990 ACR criteria (5). Of the ﬁve
remaining studies, two (12,13) relied on a physician’s
clinical diagnosis; one (14) classiﬁed survey respon-
dents according to whether they reported having
received a diagnosis of FM and/or one of the other
pain conditions under study; one (15) did not report
on the system used to classify FM or the other health
conditions under study; and, one (16) deﬁned FM
using the 1990 ACR criteria for widespread pain but
not on the presence of tender points [which was the
same deﬁnition used by two (17,18) other studies
to deﬁne ‘chronic widespread pain’ (CWP)]. Of the
14 studies that also examined another pain condi-
tion, 11 (79%) used published criteria (19–26) to
classify participants into the respective diagnostic
group.
Health status measures
All studies reviewed measured health status with the
SF-36 (n ¼ 34) or the SF-12 (n ¼ 3). The SF-36 and
SF-12 have been validated in multiple languages
(10,11,18,27–31). The SF-36 produces eight scale
scores for eight domains of health status: physical
functioning, role functioning difﬁculties caused
by physical problems, bodily pain, general health,
vitality, social functioning, role functioning difﬁcul-
ties caused by emotional problems and mental
health. Scale scores range from 0 to 100, with higher
scores indicating better functioning. Table 1 shows
SF-36 normative data for MOS patients with ﬁve dif-
ferent health conditions: hypertension, recent acute
myocardial infarction (MI), type II diabetes, chronic
obstructive pulmonary disorder (COPD) and clinical
depression. Comparing FM scores to the published
norms can help place the health status of FM into
context.
SF-36 scale scores can be used to derive two sum-
mary measures of health status: physical component
summary (PCS) and mental component summary
(MCS). The PCS includes scales assessing physical
functioning, role functioning difﬁculties caused by
physical problems, bodily pain and general health.
The MCS includes scales assessing vitality, social
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emotional problems and mental health. The PCS and
MCS are standardised to reﬂect a general population
mean of 50 and a SD of 10. Higher scores represent
better functioning.
The SF-12 was derived from the SF-36 (11). The
SF-12 measures the same health status concepts as
the SF-36. However, the SF-12 version 1 (11) (the
only version studies used in this review) only yields
scores for the physical (PCS) and mental (MCS)
Table 2 SF-36 scores among persons in the general population of the Netherlands, by pain condition (14, p. 725)
Pain condition group n
Mean SF-36 Scale Scores (SE)
PF RP BP GH VT SF RE MH
FM 43 55.0 (3.2) 41.4 (5.8) 48.2 (3.6) 50.1 (3.0) 39.9 (3.1) 60.3 (3.4) 81.5 (4.8) 64.1 (2.6)
Herniated disk 368 73.2 (1.1) 65.8 (2.0) 67.3 (1.3) 62.9 (1.1) 61.4 (1.1) 77.7 (1.2) 82.6 (1.7) 73.2 (0.9)
Gout 138 75.6 (2.0) 68.1 (3.6) 70.2 (2.2) 64.7 (1.9) 60.8 (1.9) 79.1 (2.2) 78.7 (3.0) 73.2 (1.7)
Repetitive strain injury 63 73.5 (2.5) 65.1 (4.4) 64.5 (2.7) 64.9 (2.3) 60.2 (2.4) 79.2 (2.7) 82.7 (3.7) 72.8 (2.0)
Epicondylitis 418 80.5 (1.1) 68.1 (1.9) 71.0 (1.2) 67.8 (1.0) 63.1 (1.0) 82.4 (1.1) 82.8 (1.6) 75.1 (0.9)
OA of knee 547 67.6 (1.0) 61.0 (1.9) 62.7 (1.1) 60.1 (1.0) 58.8 (1.0) 75.7 (1.1) 80.4 (1.6) 72.0 (0.9)
OA of hip 354 62.4 (1.4) 52.8 (2.5) 59.1 (1.5) 60.0 (1.3) 56.8 (1.3) 73.2 (1.5) 80.5 (2.1) 73.5 (1.2)
Osteoporosis 280 64.3 (1.4) 55.9 (2.6) 60.9 (1.6) 58.6 (1.3) 56.7 (1.4) 69.8 (1.6) 77.2 (2.2) 68.9 (1.2)
Whiplash 79 72.3 (2.3) 57.6 (4.2) 62.7 (2.6) 63.0 (2.2) 58.3 (2.3) 77.3 (2.5) 78.0 (3.5) 72.3 (1.9)
RA 156 62.3 (2.0) 49.0 (3.5) 58.0 (2.2) 52.1 (1.8) 52.2 (1.9) 70.3 (2.1) 72.3 (3.0) 69.2 (1.6)
Other chronic arthritis 155 65.0 (1.9) 54.7 (3.4) 57.3 (2.1) 53.3 (1.8) 54.5 (1.8) 69.9 (2.0) 74.1 (2.8) 70.7 (1.6)
Tendinitis and capsulitis 587 75.3 (0.8) 62.9 (1.5) 66.2 (0.9) 63.1 (0.8) 60.5 (0.8) 79.4 (0.9) 83.4 (1.3) 73.8 (0.7)
No pain condition listed above 1888 87.8 (0.5) 85.8 (0.8) 84.1 (0.5) 72.8 (0.4) 69.3 (0.5) 87.6 (0.5) 89.8 (0.8) 79.7 (0.4)
SF-36, short-form health survey (36 item): PF, physical functioning; RP, role functioning difﬁculties caused by physical problems; BP, bodily pain; GH, general health;
VT, vitality; SF, social functioning; RE, role functioning difﬁculties caused by emotional problems; MH, mental health. Higher scores indicate better health status. Pain
conditions: FM, ﬁbromyalgia; OA, osteoarthritis; RA, rheumatoid arthritis.
Bold font indicates a signiﬁcant (p < 0.05) difference between the FM group and the other pain condition group.
Table 1 Normative data for the SF-36
n
Mean SF-36 Scale Scores (SD)
PF RP BP GH VT SF RE MH
General population
US general population in 1998 (10) 2474 84.2 (23.3) 81.0 (34.0) 75.2 (23.4) 72.0 (20.3) 60.9 (21.0) 83.3 (23.0) 81.3 (33.0) 74.7 (18.1)
US general population in 1998,
women age 45–54* (10)
193 82.9 (21.7) 80.0 (35.4) 72.1 (23.3) 70.5 (20.6) 60.6 (21.3) 82.7 (20.8) 81.9 (33.3) 74.4 (18.1)
Dutch general population in 1998 (14) 3664 82.5 (24.8) 77.7 (37.8) 80.2 (23.6) 69.4 (19.6) 65.9 (20.0) 84.2 (23.1) 87.2 (30.6) 77.3 (17.1)
MOS patient norms (10)
Hypertension 2089 73.4 62.0 72.3 63.3 58.3 86.7 76.7 77.9
Recent acute MI 107 69.7 51.4 72.6 59.2 57.7 84.6 73.5 75.8
COPD 85 56.9 34.4 54.8 45.3 44 71.8 59.7 68.1
Congestive heart failure 216 47.5 34.4 62.7 47.1 44.3 71.3 63.7 74.7
Type II diabetes 541 67.8 56.6 68.5 56.1 55.7 82.0 75.6 76.74
Clinical depression 502 71.6 44.4 58.8 52.9 40.1 57.2 38.9 46.3
SF-36, short-form health survey (36 item): PF, physical functioning; RP, role functioning difﬁculties caused by physical problems; BP, bodily pain; GH, general health; VT,
vitality; SF, social functioning; RE, role functioning difﬁculties caused by emotional problems; MH, mental health. Higher scores indicate better health status. Patient
norms: MOS, Medical Outcomes Study; MI, myocardial infarction; COPD, chronic obstructive pulmonary disorder; HTN/OA, comorbid hypertension and osteoarthritis.
*Normative data are presented for this demographic group because FM study groups typically comprised female patients whose average age fell within the range of
45–54 years.
Weighted for the Dutch age-sex population.
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PCS and MCS scores is the same as that described
for the SF-36 PCS and MCS scores described above.
Presentation of ﬁndings
Findings are presented in four sections. Section 1
describes ﬁndings from general population surveys.
General population surveys collect data from people
randomly selected from the community. An advan-
tage of general population surveys is that ﬁndings
are not biased by help-seeking. The term ‘respon-
dent’ is used when describing ﬁndings from general
population surveys. Section 2 describes ﬁndings from
cross-sectional studies that recruited patients from
outpatient medical settings. Section 3 describes ﬁnd-
ings from FM clinical trials. FM clinical trials are the
only longitudinal studies in this review. Health status
scores are described for the total study sample at
baseline. Discussion of treatment outcomes is limited
to the number of trials that found a signiﬁcant
change from baseline on one or more aspects of
health status. It is beyond the scope of this review to
provide a detailed discussion of treatment effects
associated with different therapies. Section 4
describes the extent to which impairments of people
with FM are because of the presence of FM itself as
opposed to the presence of a concurrent pain condi-
tion. Findings help to show the extent to which FM
contributes to the overall health status burden in
afﬂicted persons. In each section, tables present mean
SF-36 or SF-12 scores, when numeric score values
were reported in the original publications. Differ-
ences based on a statistical analysis with p-values of
< 0.05 are described in the text.
Statistical analysis
This review presents ﬁndings as reported in the ori-
ginal publications, with two exceptions where we
performed our own analysis on the published data.
In section 1, published SF-36 data from a Dutch gen-
eral population study (14) were used to test for dif-
ferences between the FM group and each of the
other 11 pain condition groups under study. The dif-
ference between the two groups was considered to be
signiﬁcant at the 0.05 level, it was larger than 1.96
times the square root of the sum of the squared stan-
dard errors of both groups (14, p. 724). In section 3,
when baseline health status data were presented sepa-
rately for treatment groups rather than for the total
clinical trial sample, we calculated mean values for
the total sample by averaging scores across treatment
groups.
Results
Section 1: general population surveys
The SF-36 was used to examine the health status of
people with FM and various other pain conditions in
the general populations of the Netherlands (14;
Table 2) and Sweden (17) (data not shown). People
in each of the pain condition groups had signiﬁ-
cantly lower (poorer) mean scores on all eight health
status domains compared with people in the general
population (14,17). Health status impairments
among people with FM were especially pronounced.
People with FM had similar, and in most cases sig-
niﬁcantly lower, health status scores compared with
those in various other pain condition groups
(Table 2). Study groups with FM and CWP also
scored signiﬁcantly lower than the group with
chronic regional pain on all eight health status
domains (17). Findings highlight that people with
FM in the general population have a poorer overall
health status than those with widely accepted pain
conditions, including RA, OA and osteoporosis.
Section 2: cross-sectional clinical studies
Fibromyalgia study participants recruited from out-
patient medical centres had signiﬁcantly lower scores
than healthy controls on all eight SF-36 health status
domains and the two SF-12 physical and mental
summary scales (Table 3). FM patient groups also
Table 4 SF-36 scores in male and female FM patients
Reference (country)
Study groups n
Mean age
(SD)
SF-36 health survey scores (SD)
PF RP BP GH VT SF RE MH
Buskila et al. (2000) (51) (Israel)
FM males 40 45.0 (13.0) 40.6 (24.1) 8.3 (18.4) 24.9 (17.0) 26.9 (14.6) 36.3 (19.7) 32.4 (26.4) 23.9
a (41.8) 46.5 (17.5)
FM females 40 46.0 (10.0) 33.6 (25.1) 11.3 (23.3) 27.9 (14.5) 32.6 (13.7) 39.8 (12.3) 37.2 (21.4) 60.8 (38.4) 50.4 (10.6)
SF-36, short-form health survey (36 items): PF, physical functioning; RP, role functioning difﬁculties caused by physical problems; BP, bodily pain; GH, general health;
VT, vitality; SF, social functioning; RE, role functioning difﬁculties caused by emotional problems; MH, mental health. Higher scores indicate better health status.
aFM males differed signiﬁcantly from FM females, p < 0.001.
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patients with other speciﬁc pain conditions, includ-
ing myofacial pain syndrome (MPS), SLE, CWP, RA
and primary Sjo ¨gren’s syndrome (prim SS) [Table 3
and data not shown (18,32)]. FM groups scored sig-
niﬁcantly lower than other speciﬁc patient groups on
physical functioning [compared with SLE (16), CWP
(18), prim SS (32)]; role functioning difﬁculties
caused by physical problems [compared with SLE
(16), CWP (18), RA (33), prim SS (32)]; bodily pain
[compared with MPS (34), SLE (16), CWP (18), RA
(32,33) and prim SS (32)]; general health [compared
with MPS (34), CWP (18), RA (32)]; vitality [com-
pared with MPS (34), SLE (16), CWP (18), RA
(32,33) and prim SS (32)]; social functioning [com-
pared with CWP (18) and RA (32,33)]; role difﬁcul-
ties caused by emotional problems [compared with
MPS (34), SLE (16) and RA (32,33)] and mental
health [compared with SLE (16) and RA (32,33)].
Examination of health status summary scores showed
that FM patients had a signiﬁcantly poorer physical
health status and a similar mental health status com-
pared with SLE patients; the opposite pattern was
observed when comparing summary scores for
patients with FM and RA (Table 3).
Only one study in the current review found a bet-
ter health status for the FM group than for the com-
parison pain group. FM patients had a signiﬁcantly
better health status scores than patients with low back
pain (LBP) on the domains of bodily pain, general
health, social functioning, role functioning caused by
emotional problems and mental health (35). This
study was limited by a very small sample size (n ¼ 14
and n ¼ 10 for FM and LBP respectively). Additional
studies are required to examine the differential health
status burden of these conditions.
Fibromyalgia was found to be a common and
debilitating condition among patients referred to
rheumatology because of pain. Of 86 patients with
CWP referred to rheumatology, 37 (43%) were
found to have previously undiagnosed FM (18). In
addition, FM was identiﬁed as the most common
diagnosis in a group of 145 US Persian War veterans
who were referred for rheumatology consultation for
medically unexplained symptoms (n ¼ 49; 34%)
(36). Of the 49 patients with FM, 38 (76%) were
males (36). Both studies found FM groups to have
signiﬁcantly poorer health status scores than those
without FM (18,36). Findings highlight that FM neg-
atively affects both males and females.
Several studies focussed exclusively on the health
status of female patients with FM. However, one
study compared health status proﬁles of male and
female patients with FM. Although both males and
females with FM had poor health status scores, male
FM patients had signiﬁcantly lower scores than
female FM patients on the domain assessing role
functioning difﬁculties caused by emotional problems
(Table 4). Although FM is less common in males
than in females, males with FM may be at even
greater risk for experiencing reduced health status
than their female counterparts.
Section 3: FM clinical trials
A total of 14 FM clinical trials included assessment
of health status using the SF-36 or the SF-12
(Table 5). These trials examined the impact of a vari-
ety of pharmacological and non-pharmacological
treatments for FM. Before receiving a new treatment,
trials participants had poor health status scores
(Table 5). All of the trials reported a signiﬁcant
improvement from baseline on at least one aspect of
Table 6 SF-36 scores of people in the general population, by number of pain conditions
Reference (country)
Study groups n
SF-36 health survey scores (SD)
PF RP BP GH VT SF RE MH
Picavet et al. (2003) (14, p.725)
(the Netherlands)
3664
1 pain condition* 957 80.0 (0.6) 74.3 (1.2) 73.8 (0.7) 67.7 (0.6) 64.6 (0.6) 83.2 (0.7) 86.7 (1.0) 76.0 (0.6)
2 pain conditions* 478 72.7 (1.0) 63.0 (1.8) 65.5 (1.0) 64.0 (0.9) 60.2 (1.0) 79.6 (1.1) 84.0 (1.5) 73.8 (0.8)
3 pain conditions* 193 63.4 (1.6) 53.2 (3.0) 57.0 (1.8) 55.8 (1.6) 56.0 (1.6) 69.1 (1.8) 76.0 (2.6) 69.9 (1.4)
No pain condition* 1888 87.8 (0.5) 85.8 (0.8) 84.1 (0.5) 72.8 (0.4) 69.3 (0.5) 87.6 (0.5) 89.8 (0.8) 79.9 (0.4)
Any pain condition* 1776 75.2 (0.5) 67.1 (0.9) 68.5 (0.6) 64.6 (0.5) 61.6 (0.5) 79.8 (0.6) 83.7 (0.8) 74.3 (0.4)
SF-36, short-form health survey (36 items); PF, physical functioning; RP, role functioning difﬁculties caused by physical problems; BP, bodily pain; GH, general health;
VT, vitality; SF, social functioning; RE, role functioning difﬁculties caused by emotional problems; MH, mental health; PCS, physical component summary; MCS,
mental component summary. Higher scores indicate better health status.
*Table 2 shows speciﬁc pain conditions.
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cebo-controlled trials (37–39) showed signiﬁcant
improvements favouring an active treatment vs. pla-
cebo on speciﬁc physical and mental health status
domains. It is beyond the score of this review to
describe the magnitude of treatment effects associ-
ated with the different interventions. However, ﬁnd-
ings suggest that effective treatment can lead to
signiﬁcant improvements in aspects of both physical
and mental health status.
Section 4: health status proﬁles of FM groups
with and without a concurrent pain condition
People with a speciﬁc pain condition commonly had
at least one concurrent (i.e. coexisting) pain condi-
tion (Table 6; Figure 1). Health status deteriorated in
conjunction with the number of pain conditions
present (Table 6; Figure 1). This pattern was
observed for ﬁve speciﬁc pain conditions, including
FM (Figure 1). Importantly, however, FM remained
signiﬁcantly impairing even when it occurred alone.
Respondents with FM alone had standardised scores
that were 1 SD below the general population in the
areas of bodily pain and vitality (Figure 1). This pat-
tern of ﬁndings was unique to FM (Figure 1). Find-
ings highlight that impaired bodily pain and
decreased vitality are core features of FM. Future
studies with larger samples without concurrent health
conditions are required to conﬁrm ﬁndings.
Several studies examined the extent to which FM
contributed to the overall health status burden of
patients with and without a speciﬁc concurrent con-
dition (Table 7). The presence of FM added to the
health status impairment among patients who also
had migraine, RA or SLE (Table 7). In contrast,
headache did not signiﬁcantly add to the health sta-
tus burden of patients with FM (Table 7). Findings
highlight that FM uniquely contributes to the overall
health status burden in affected persons.
The extent to which FM was associated with men-
tal and physical health status was examined, after
adjusting for the presence of non-rheumatic chronic
diseases and sociodemographic characteristics (1).
Health status was examined using the SF-12. FM was
the only pain condition uniquely associated with the
mental component of health status (adjusted MCS
30.0, 95% CI 34.6–43.4) but not the physical compo-
nent of health status (adjusted PCS 33.9, 95% CI
29.3–38.5). The opposite pattern was observed for
RA (adjusted PCS 29.1, 95% CI 21.9–36.2; adjusted
MCS 42.8, 95% CI 36.4–49.2), OA of the knee
(adjusted PCS 31.7, 95% CI 27.3–36.1; adjusted MCS
43.9, 95% CI 39.8–48.0) and LBP (adjusted PCS
32.4, 95% CI 28.0–36.8; adjusted MCS 43.0, 95%
38.8–47.2).
Discussion
Studies performed around the world showed that
people with FM had a remarkably consistent pattern
of health status impairment. People with FM scored
signiﬁcantly lower on all eight health status domains
compared with people in the general population. FM
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Figure 1 Patterns of health status for pain conditions
compared with the general population. SF-36 scores
expressed as number of standard deviations from the
population mean. PF, physical functioning; RP, role
functioning difﬁculties caused by physical problems; BP,
bodily pain; GH, general health; VT, vitality; SF, social
functioning; RE, role functioning difﬁculties caused by
emotional problems; MH, mental health. Picavet HSJ,
Hoeymans N. Health related quality of life in multiple
musculoskeletal diseases: SF-36 and EQ-5D in the DMC3
study. Annals of the Rheumatic Diseases 2004; 63; 723–729.
Adapted with permission from the BMJ Publishing Group
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SD below the general population mean and physical
health summary scores that fell 2 SD below the
general population mean. People with FM also had
similar or signiﬁcantly lower scores on all eight
health status domains compared to people with other
speciﬁc pain conditions, including RA, OA, SLE,
prim SS and MPS (14,16,32–34). FM groups had sig-
niﬁcantly lower scores than all of the speciﬁc pain
conditions described above on domains of bodily
pain and vitality (14,16,32–34).
To provide a broader interpretive context for
understanding the health status burden of FM, SF-36
scale scores of FM patient groups can be compared
with those of norms for MOS patients (Table 3 and
Table 1). Without exception, FM patient groups had
numerically lower scores on all eight health status
domains compared with norms for MOS patients
with hypertension, recent acute MI and type II dia-
betes. Similar ﬁndings were observed when FM
scores were compared with norms for MOS patients
with congestive heart failure and chronic obstructive
pulmonary disease, with an occasional exception
where a numerically higher score was found for a
FM group on a physical status domain. Compared
with norms for MOS patients with depression, FM
groups consistently had numerically lower scores on
physical domains, but not on mental domains assess-
ing role difﬁculties caused by emotional problems
and mental health. These are the only two SF-36
domains that exclusively measure mental aspects of
health status. Although based on numerical compari-
sons as opposed to statistical analysis, these ﬁndings
suggest that the overall health status burden of FM is
at least as great in magnitude as that of a variety of
health conditions widely accepted as impairing.
Studies in this review primarily reported on the
health status of women. Two studies, however,
showed that FM also reduced the health status of
males. A study comparing health status proﬁles of
male and female FM patients showed that males had
an even poorer health status than females (18). In
addition, FM was the most common diagnosis in
145 US veterans who were referred for rheumatologic
evaluation for medically unexplained symptoms (36).
Most (76%) of these FM patients were male. Find-
ings highlight that FM also imposes a signiﬁcant
health status burden on males.
Health status impairments of people with FM
could not be fully explained by the presence of other
concurrent health conditions. People with FM (both
with and without another concurrent pain condition)
had standardised scores that were at least 1 SD below
the general population mean on domains of bodily
pain and vitality (14). This pattern of ﬁndings was
unique to people with FM. Findings highlight that
impairments in bodily pain and vitality are central
features of FM. Moreover, FM signiﬁcantly added to
physical and mental health status impairments in
patients who also had migraine, SLE or RA
(12,40–42). In contrast, headache did not add signiﬁ-
cantly to the overall health status burden in FM
patients (43). Together, ﬁndings underscore that FM
makes a unique contribution to the health status
burden of people with the condition.
This review is subject to several limitations. First,
we only considered studies that measured health sta-
tus with the SF-36 and the SF-12. However, these
generic instruments permit comparisons across
groups with and without FM while disease-speciﬁc
instruments do not. Second, all health status data
were based on self-report. However, as no objective
clinical markers exist for FM in routine clinical prac-
tice, clinical decisions depend on FM patients’ self-
reported symptoms, treatment side effects and their
combined impact on health status. The centrality of
the patient’s point of view is also emphasised in
clinical research (10,44). Third, many of the stud-
ies in this review had small sample sizes. However,
even with the small sample sizes, signiﬁcant differ-
ences were observed between groups with and with-
out FM. These studies also revealed a consistent
pattern of health status impairment among people
with FM.
Although FM is a controversial construct, studies
performed around the world showed that people
with FM have substantial impairments in both physi-
cal and mental health status. People with FM had a
health status burden that was greater in magnitude
compared to those with health conditions that are
widely accepted as impairing. Findings from FM
clinical trials suggest that efﬁcacious treatments can
improve aspects of health status, although ﬁndings
require conﬁrmation in usual care settings. Findings
in this review underscore the importance of address-
ing the substantial health status burden of people
with FM, irrespective of current debate about how
FM should be classiﬁed.
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